Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

10.15252/emmm.201505889

Saved in:

Bibliographic Details
Main Authors:	Regula, J.T, Lundh von Leithner, P, Foxton, R, Barathi, V.A, Cheung, C.M.G, Bo Tun, S.B, Wey, Y.S, Iwata, D, Dostalek, M, Moelleken, J, Stubenrauch, K.G, Nogoceke, E, Widmer, G, Strassburger, P, Koss, M.J, Klein, C, Shima, D.T, Hartmann, G
Other Authors:	OPHTHALMOLOGY
Format:	Article
Published:	2020
Subjects:	angiopoietin 2 CD16 antigen monoclonal antibody rg 7716 unclassified drug vasculotropin A vasculotropin A antibody vasculotropin antibody immunologic factor angiogenesis animal experiment animal model Article binding site cross reaction drug clearance drug efficacy drug potency drug protein binding eye disease human monotherapy mouse nonhuman priority journal protein depletion protein targeting retina edema retina vasculitis subretinal neovascularization upregulation vitreous body animal antagonists and inhibitors disease model Eye Diseases isolation and purification Macaca fascicularis Neovascularization, Pathologic pathology preclinical study treatment outcome Angiopoietin-2 Animals Antibodies, Monoclonal Disease Models, Animal Drug Evaluation, Preclinical Immunologic Factors Treatment Outcome Vascular Endothelial Growth Factor A
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/179906
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-179906
record_format	dspace
spelling	sg-nus-scholar.10635-1799062024-04-12T05:49:04Z Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases Regula, J.T Lundh von Leithner, P Foxton, R Barathi, V.A Cheung, C.M.G Bo Tun, S.B Wey, Y.S Iwata, D Dostalek, M Moelleken, J Stubenrauch, K.G Nogoceke, E Widmer, G Strassburger, P Koss, M.J Klein, C Shima, D.T Hartmann, G OPHTHALMOLOGY DUKE-NUS MEDICAL SCHOOL angiopoietin 2 CD16 antigen monoclonal antibody rg 7716 unclassified drug vasculotropin A vasculotropin A antibody vasculotropin antibody angiopoietin 2 immunologic factor monoclonal antibody vasculotropin A angiogenesis animal experiment animal model Article binding site cross reaction drug clearance drug efficacy drug potency drug protein binding eye disease human monotherapy mouse nonhuman priority journal protein depletion protein targeting retina edema retina vasculitis subretinal neovascularization upregulation vitreous body animal antagonists and inhibitors disease model Eye Diseases isolation and purification Macaca fascicularis Neovascularization, Pathologic pathology preclinical study treatment outcome Angiopoietin-2 Animals Antibodies, Monoclonal Disease Models, Animal Drug Evaluation, Preclinical Eye Diseases Immunologic Factors Macaca fascicularis Neovascularization, Pathologic Treatment Outcome Vascular Endothelial Growth Factor A 10.15252/emmm.201505889 EMBO Molecular Medicine 8 11 1265-1288 2020-10-26T05:03:19Z 2020-10-26T05:03:19Z 2016 Article Regula, J.T, Lundh von Leithner, P, Foxton, R, Barathi, V.A, Cheung, C.M.G, Bo Tun, S.B, Wey, Y.S, Iwata, D, Dostalek, M, Moelleken, J, Stubenrauch, K.G, Nogoceke, E, Widmer, G, Strassburger, P, Koss, M.J, Klein, C, Shima, D.T, Hartmann, G (2016). Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Molecular Medicine 8 (11) : 1265-1288. ScholarBank@NUS Repository. https://doi.org/10.15252/emmm.201505889 17574676 https://scholarbank.nus.edu.sg/handle/10635/179906 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	angiopoietin 2 CD16 antigen monoclonal antibody rg 7716 unclassified drug vasculotropin A vasculotropin A antibody vasculotropin antibody angiopoietin 2 immunologic factor monoclonal antibody vasculotropin A angiogenesis animal experiment animal model Article binding site cross reaction drug clearance drug efficacy drug potency drug protein binding eye disease human monotherapy mouse nonhuman priority journal protein depletion protein targeting retina edema retina vasculitis subretinal neovascularization upregulation vitreous body animal antagonists and inhibitors disease model Eye Diseases isolation and purification Macaca fascicularis Neovascularization, Pathologic pathology preclinical study treatment outcome Angiopoietin-2 Animals Antibodies, Monoclonal Disease Models, Animal Drug Evaluation, Preclinical Eye Diseases Immunologic Factors Macaca fascicularis Neovascularization, Pathologic Treatment Outcome Vascular Endothelial Growth Factor A
spellingShingle	angiopoietin 2 CD16 antigen monoclonal antibody rg 7716 unclassified drug vasculotropin A vasculotropin A antibody vasculotropin antibody angiopoietin 2 immunologic factor monoclonal antibody vasculotropin A angiogenesis animal experiment animal model Article binding site cross reaction drug clearance drug efficacy drug potency drug protein binding eye disease human monotherapy mouse nonhuman priority journal protein depletion protein targeting retina edema retina vasculitis subretinal neovascularization upregulation vitreous body animal antagonists and inhibitors disease model Eye Diseases isolation and purification Macaca fascicularis Neovascularization, Pathologic pathology preclinical study treatment outcome Angiopoietin-2 Animals Antibodies, Monoclonal Disease Models, Animal Drug Evaluation, Preclinical Eye Diseases Immunologic Factors Macaca fascicularis Neovascularization, Pathologic Treatment Outcome Vascular Endothelial Growth Factor A Regula, J.T Lundh von Leithner, P Foxton, R Barathi, V.A Cheung, C.M.G Bo Tun, S.B Wey, Y.S Iwata, D Dostalek, M Moelleken, J Stubenrauch, K.G Nogoceke, E Widmer, G Strassburger, P Koss, M.J Klein, C Shima, D.T Hartmann, G Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
description	10.15252/emmm.201505889
author2	OPHTHALMOLOGY
author_facet	OPHTHALMOLOGY Regula, J.T Lundh von Leithner, P Foxton, R Barathi, V.A Cheung, C.M.G Bo Tun, S.B Wey, Y.S Iwata, D Dostalek, M Moelleken, J Stubenrauch, K.G Nogoceke, E Widmer, G Strassburger, P Koss, M.J Klein, C Shima, D.T Hartmann, G
format	Article
author	Regula, J.T Lundh von Leithner, P Foxton, R Barathi, V.A Cheung, C.M.G Bo Tun, S.B Wey, Y.S Iwata, D Dostalek, M Moelleken, J Stubenrauch, K.G Nogoceke, E Widmer, G Strassburger, P Koss, M.J Klein, C Shima, D.T Hartmann, G
author_sort	Regula, J.T
title	Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
title_short	Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
title_full	Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
title_fullStr	Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
title_full_unstemmed	Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
title_sort	targeting key angiogenic pathways with a bispecific crossmab optimized for neovascular eye diseases
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/179906
_version_	1800914571779637248

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

Similar Items